Vertical: CNMBase Year: 2025
Market Size (2025)
$119.70M
Projected (2032)
$168.42M
CAGR (2022–2032)
5.0%
Key Players
11+
Market Overview
The global enramycin market was valued at USD 119.71 Million in 2025, up from USD 103.38 Million in 2022, and is projected to reach USD 168.42 Million by 2032, registering a CAGR of 5.00% over 2026–2032. In absolute terms, the market is expected to add USD 48.71 Million between 2025 and 2032. Enramycin is a polypeptide antibiotic produced by fermentation of Streptomyces fungicidicus and used in feed for poultry and swine, principally for the control of Clostridium perfringens and necrotic enteritis and, in jurisdictions where it remains permitted, for improving feed efficiency. Demand is anchored in Asia Pacific and Latin America, where large integrated broiler and pig production systems continue to rely on in-feed Gram-positive antibacterials, and is moderated in Europe and other markets with long-standing prohibitions on antibiotic growth promoters.
Market growth over the forecast period is supported by rising global poultry meat output, the recurring economic burden of necrotic enteritis in broiler flocks, and the shift of the protein industry toward large, feed-mill-integrated operations that purchase premixed medicated feed ingredients. At the same time, the market operates under steadily tightening antimicrobial-use policy, including the September 2024 United Nations Political Declaration on Antimicrobial Resistance, national action plans in China, India and Brazil, and trade-linked requirements on antimicrobial use in exporting countries. These forces shape a market that is growing steadily rather than rapidly, with value increasingly concentrated in regulated, veterinary-supervised prevention and treatment applications.
Key Findings
By livestock, Poultry was the largest segment in 2025 at USD 71.82 Million, accounting for 60.0% of global revenue, while Others is the fastest-growing segment with a CAGR of 5.65% over 2026–2032.
By physical form, Premix was the largest segment in 2025 at USD 95.76 Million (80.0% share) and is also the fastest-growing form, with a CAGR of 5.36%.
By region, Asia Pacific led the market in 2025 with USD 65.84 Million (55.0% share), while Middle East & Africa is the fastest-growing region at a CAGR of 6.23%.
At country level, China was the leading market in 2025 at USD 34.236 Million, and India is the fastest-growing country with a CAGR of 7.38%, marginally ahead of Saudi Arabia at 7.37%.
Segmentation Summary
The livestock segmentation is dominated by poultry, reflecting the role of enramycin in the control of necrotic enteritis in broilers, the species in which Clostridium perfringens infection carries the greatest economic cost. Poultry is projected to grow from USD 71.82 Million in 2025 to USD 103.07 Million in 2032. Swine accounted for 30.0% of the market in 2025 and is expected to grow at a CAGR of 4.16%, the slowest of the three livestock segments, as several large pig-producing countries restrict in-feed antibiotic use. The Others segment, which covers remaining livestock categories, is small at USD 11.97 Million but posts the highest livestock CAGR at 5.65%.
By physical form, premix accounted for 80.0% of 2025 revenue. Premixes, typically supplied at 4%, 8% or 10% active concentration on an inert carrier, are the standard way in which enramycin enters compound feed and are preferred by feed mills for dosing accuracy and handling safety. The Others form segment, valued at USD 23.94 Million in 2025, is forecast to grow at 3.42%, below the market average.
Competitive Landscape Summary
The enramycin market is moderately fragmented. The originator brand, Enradin, is marketed by MSD Animal Health (Merck Animal Health in the United States and Canada), which positions it on documented potency and originator quality. A large share of global active-ingredient and premix volume is produced by Chinese fermentation-based manufacturers, including Apeloa Pharmaceutical, which manufactures Enradin F-80 for MSD, Hebei Shengxue Dacheng Pharmaceutical, in which China Animal Husbandry Industry Co. agreed in 2026 to acquire a controlling stake, Shandong Shengli Bioengineering and Zhejiang Dayang Biotech Group. Regional brand owners such as Ourofino Saúde Animal in Brazil and Square Pharmaceuticals in Bangladesh, along with export-oriented generic suppliers, complete the landscape. Competition centres on price, product potency and consistency, registration coverage and access to integrated poultry producers and feed mills.
Challenges and Opportunities
The principal challenge for the market is regulatory: antibiotic growth promoters have been banned in the European Union since 2006, growth-promotion claims for drug feed additives were withdrawn in China from 2020, and Thailand, South Korea, Indonesia, Vietnam and Argentina have restricted in-feed antibiotic use. Enramycin also faces competition from alternative necrotic enteritis control tools, including probiotics, organic acids, phytogenic additives and vaccines, and from other Gram-positive antibacterials such as avilamycin and bacitracin. Opportunities arise from expanding broiler production in India, Southeast Asia, the Middle East and Latin America, from regulatory change that removes competing growth promoters while leaving enramycin available, as with Brazil's April 2026 prohibition of bacitracin and virginiamycin as growth promoters, and from repositioning enramycin around veterinary-supervised necrotic enteritis prevention and treatment, supported by its lack of use in human medicine and its negligible absorption from the gut.
Future Outlook
Between 2026 and 2032, the global market is expected to expand from USD 125.70 Million to USD 168.42 Million. Asia Pacific is projected to remain the core of demand, rising to USD 93.13 Million by 2032, while Latin America and the Middle East & Africa gain share on the back of poultry-led growth. Suppliers able to demonstrate consistent potency, maintain product registrations as rules evolve and support customers with technical service on gut-health programmes are best positioned to capture this growth.
The Enramycin Market market is projected to grow at a CAGR of 5.0% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Enramycin (also known as enduracidin; CAS No. 11115-82-5) is a lipodepsipeptide antibiotic complex produced by fermentation of the actinomycete Streptomyces fungicidicus. Its main components, enramycin A (C107H138Cl2N26O31) and enramycin B (C108H140Cl2N26O31), act on Gram-positive bacteria by binding lipid II and blocking the transglycosylation step of peptidoglycan cell-wall synthesis. The compound was developed in Japan in the 1960s and is used exclusively in animals: it has no application in human medicine and is very poorly absorbed from the intestinal tract, so it acts locally in the gut. In poultry and swine it is used to control Clostridium perfringens, the causative agent of necrotic enteritis, and, in jurisdictions that permit it, to improve weight gain and feed conversion.
For the purposes of this study, the global enramycin market comprises the value of enramycin products sold for use in livestock, including enramycin premixes (typically 4%, 8% and 10% enramycin on a carrier such as corn cob or maize meal) and enramycin supplied in other physical forms. Market value is measured at the level of products sold to feed manufacturers, integrators, distributors and livestock producers.
The study excludes compound feed into which enramycin has been incorporated (only the value of the enramycin product is counted), other polypeptide antibiotics such as bacitracin, colistin and avilamycin, non-antibiotic gut-health additives such as probiotics, organic acids and phytogenics, and research-grade enramycin reagents.
Scope of the Study
Segmentation by livestock: Poultry, Swine, Others.
Segmentation by physical form: Premix, Others.
Regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level analysis for the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Rest of Europe, China, India, Japan, Rest of Asia Pacific, Brazil, Argentina, Rest of Latin America, UAE, Saudi Arabia, South Africa and Rest of MEA.
Timeline: historic years 2022, 2023 and 2024; base year 2025; forecast years 2026–2032; CAGR period 2026–2032.
Currency and unit: all values are presented in USD Million.
Research Objectives
To estimate the size of the global enramycin market for 2022–2025 and to forecast it for 2026–2032 in USD Million.
To analyse the market by livestock (poultry, swine, others) and by physical form (premix, others), identifying the largest and fastest-growing segments.
To assess the market across five regions and twenty countries and country groups, and to identify the regional and country-level demand centres.
To evaluate the drivers, restraints, opportunities, trends and challenges affecting enramycin demand, including necrotic enteritis pressure and antimicrobial-use policy.
To examine the regulatory status of enramycin and in-feed antibiotics in major producing and consuming countries.
To map the enramycin value chain from fermentation inputs to end users and assess industry structure through Porter's Five Forces and PESTEL analysis.
To identify and position the leading manufacturers and suppliers of enramycin and to track their key developments from 2022 onward.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured research process combining secondary research, primary research with industry participants, and quantitative modelling. The process began with a definition of the market scope and segmentation, followed by collection of data on livestock populations, feed production, regulatory status and supplier activity. Market estimates were then built using top-down and bottom-up approaches, triangulated, and validated through primary discussions before the forecast was developed.
Stage 1: Market definition, scope setting and segmentation design.
Stage 2: Secondary research on livestock production, compound feed output, regulation and company activity.
Stage 3: Primary research with supply-side and demand-side participants.
Stage 4: Market size estimation using top-down and bottom-up models and data triangulation.
Stage 5: Forecasting, validation and report preparation.
Secondary Research
Secondary research provided the foundation for understanding the market structure, regulatory environment and demand base. Sources relevant to the enramycin industry included:
Government and regulatory bodies: ministries of agriculture and veterinary authorities such as the U.S. Food and Drug Administration Center for Veterinary Medicine, China's Ministry of Agriculture and Rural Affairs, Japan's Food and Agricultural Materials Inspection Center and Food Safety Commission, Brazil's Ministry of Agriculture and Livestock, India's Department of Animal Husbandry and Dairying, and national feed and veterinary-drug registration databases.
Statistical agencies and intergovernmental organisations: livestock and meat production statistics from the USDA Foreign Agricultural Service, national statistics bureaus, the OECD-FAO Agricultural Outlook, and antimicrobial-use reporting by the World Organisation for Animal Health.
Industry associations: poultry, swine and compound-feed associations at national and regional level, and animal-health industry bodies.
Company sources: annual reports, stock-exchange filings, product registration documents, technical data sheets and press releases of animal-health companies and active-ingredient manufacturers.
Trade and scientific literature: poultry and swine trade journals, veterinary and animal-science journals covering necrotic enteritis and in-feed antibacterials, and customs and trade databases.
Paid databases: company financial databases, trade-flow databases and industry research repositories.
Primary Research
Primary research was conducted through in-depth interviews and structured discussions to validate secondary findings, obtain qualitative insight on market practice and refine market estimates.
Supply-side respondents: executives, product managers and sales heads at enramycin active-ingredient manufacturers, premix producers, animal-health companies and distributors.
Demand-side respondents: nutritionists and veterinarians at integrated poultry and swine producers, procurement managers at compound feed mills, and independent poultry and swine veterinary consultants.
Other respondents: regulatory specialists and academic researchers in animal nutrition and veterinary microbiology.
The objectives of primary research were to confirm product usage patterns by species and form, understand pricing and purchasing behaviour, assess the effect of regulation on demand, identify active suppliers and their positioning, and validate the base-year market estimates and forecast assumptions.
Market Size Estimation
Market size was estimated using a combination of top-down and bottom-up approaches.
Top-down approach: The overall veterinary in-feed antibacterial and feed additive markets were used as a starting point, and the share attributable to enramycin was derived based on regulatory status, competing products and usage patterns in each country. Regional and country values were then allocated by livestock and physical form.
Bottom-up approach: Country-level estimates were built from poultry and swine populations, compound feed production, the proportion of feed treated with enramycin, typical inclusion rates and treatment durations, and average selling prices of enramycin products. Country estimates were aggregated to regional and global totals.
Data triangulation: Results from both approaches were compared with supply-side indicators such as manufacturer capacity, trade flows and supplier revenue, and differences were reconciled through primary research to arrive at the final market estimates.
Forecasting Methodology
The forecast for 2026–2032 was developed using a factor-based model that links enramycin demand to its underlying drivers. Factors considered include projected poultry and pig meat production, growth of commercial compound feed output, necrotic enteritis incidence and control practices, the regulatory outlook for in-feed antibiotics in each country, adoption of alternative gut-health solutions, price trends for active ingredient and premix, and macroeconomic conditions. Country-level growth rates were derived from these factors and checked against historical trends for 2022–2025, and the resulting forecasts were aggregated to regional and global level and validated with industry participants.
Base Year, Forecast Period and Currency
Historic years: 2022, 2023 and 2024.
Base year: 2025.
Forecast period: 2026–2032, with CAGR calculated for 2026–2032.
Currency: all values are expressed in USD Million.
Assumptions and Limitations
Regulations governing in-feed antibiotics are assumed to evolve along currently announced policy paths; unannounced bans or approvals in major markets could alter the forecast.
Livestock production is assumed to follow current international outlooks without major disruption from animal disease outbreaks beyond those already observed.
Exchange rates are assumed to remain stable at base-year levels; values in local currencies were converted to USD at average annual rates.
Product prices are assumed to follow historical trends, with pricing pressure from generic suppliers continuing.
Enramycin product sales are not separately disclosed by most suppliers, so supplier-level revenues are not available and estimates rely on modelling and primary validation.
Market values represent the value of enramycin products only and do not include the value of the compound feed in which they are used.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global enramycin market is moderately fragmented. The originator brand, Enradin, is owned and marketed by MSD Animal Health, while most of the world's enramycin active ingredient and premix is manufactured in China by fermentation-based producers. These manufacturers supply multinational and regional brand owners under contract, market products under their own names, and sell to distributors and feed mills in export markets. A third group consists of regional brand owners and generic premix suppliers serving specific countries or emerging-market distributors.
Competition is driven by product potency and consistency, price, registration coverage in individual countries, and access to large integrators and feed mills. The originator brand competes on documented quality and efficacy, while generic suppliers compete mainly on price. Corporate activity in 2026, including China Animal Husbandry Industry Co.'s acquisition of controlling stakes in Hebei and Inner Mongolia Shengxue Dacheng Pharmaceutical, points to consolidation and vertical integration of active-ingredient supply with veterinary formulation businesses.
Key Player Positioning
Leaders
MSD Animal Health (Merck & Co., Inc.), United States: MSD Animal Health, known as Merck Animal Health in the United States and Canada, owns the Enradin brand, the reference enramycin product, marketed for necrotic enteritis control in poultry and pigs through local subsidiaries such as Intervet México and PT Intervet Indonesia. Products include Enradin F-80 and Enradin 80 (80 g/kg enramycin). Merck & Co. reported worldwide sales of USD 65.0 billion for FY2025, of which Animal Health sales were USD 6.4 billion. The company positions Enradin on originator quality against generic products and is expanding its poultry franchise, including its agreement in June 2026 to acquire TARGAN, a developer of poultry hatchery technologies.
Apeloa Pharmaceutical Co., Ltd., China: Apeloa, listed on the Shenzhen Stock Exchange, is a large active pharmaceutical ingredient, contract development and manufacturing, and formulation company with an extensive fermentation base. Its subsidiary Anhui Apeloa Biotechnology is named as the manufacturer of MSD's Enradin F-80 in Mexico. Apeloa reported revenue of RMB 9.784 billion for FY2025, with around half of first-half 2026 revenue generated overseas. Its strategy combines high-volume fermentation supply to multinational brand owners with a shift toward contract manufacturing and specialty active ingredients.
Challengers
Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. (China Animal Husbandry Industry Co., Ltd.), China: Founded in 1997, Hebei Shengxue Dacheng is a major exporter of veterinary fermentation antibiotics, with enramycin listed alongside zinc bacitracin, nosiheptide, avilamycin and colistin sulphate in its portfolio. China Animal Husbandry Industry Co., which reported FY2025 revenue of RMB 6.205 billion, announced in March 2026 the acquisition of 51% of Hebei Shengxue Dacheng and 72.7272% of Inner Mongolia Shengxue Dacheng for RMB 727 million; the company's own revenue is not publicly disclosed. The combination aims to integrate active-ingredient supply with the parent's veterinary formulation business.
Shandong Shengli Bioengineering Co., Ltd., China: Shandong Shengli Bioengineering is a fermentation-based manufacturer of veterinary antibiotic active ingredients, with enramycin among its main products together with tiamulin, flavophospholipol, monensin, salinomycin and avilamycin. It is linked to China Animal Husbandry Industry Co. and Shandong Shengli Corp. Its revenue is not publicly disclosed. The company serves export markets and domestic formulation channels, supported by regulated-market filings for tiamulin.
Zhejiang Dayang Biotech Group Co., Ltd., China: Zhejiang Dayang Biotech, listed on the Shenzhen Stock Exchange, combines potassium-salt chemicals with veterinary active ingredients, led by amprolium. It is the named manufacturer and exporter of Enragold (80 g/kg enramycin), which is registered in Brazil and imported by Ourofino. The company reported revenue of RMB 1,045.44 million for FY2025 and is expanding animal-health capacity through an 800 tonnes-per-year amprolium relocation and expansion project.
Niche Players
Ourofino Saúde Animal, Brazil: Ourofino, listed on B3, is Brazil's leading domestic animal-health company and markets Enragold, an 8% enramycin feed additive for broilers sourced from Zhejiang Dayang. It reported net revenue of BRL 1.225 billion for FY2025 and is expanding in Mexico, Colombia and Central America.
Square Pharmaceuticals PLC, Bangladesh: Square Pharmaceuticals, Bangladesh's largest pharmaceutical company, sells Necrocin Vet Powder (enramycin 8%) for necrotic enteritis through its veterinary division. It reported sales of BDT 7,628 crore for FY2024-25, as reported in the press, and serves the domestic poultry sector.
Sunny Biotech, China: Sunny Biotech, based in Hangzhou and privately held, supplies veterinary active ingredients and feed additives, including enramycin, tiamulin, colistin, bambermycin, valnemulin and nosiheptide, to export markets. Its revenue is not publicly disclosed.
Jiangxi Innovating Science & Technology, China: This privately held animal-health supplier offers enramycin 4%, 8% and 10% premixes, alongside tiamulin, tylosin and ionophores, primarily to East, South and Southeast Asian markets. Its revenue is not publicly disclosed.
AdvaCare Pharma, United States: AdvaCare Pharma, a privately held private-label and export company founded in 2005 with manufacturing in China, India and the United States, markets EnraCare enramycin premix (80 mg/g) for pigs and poultry through distributors in emerging markets. Its revenue is not publicly disclosed.
Jiangsu Ouke Animal Pharmaceutical Co., Ltd., China: Jiangsu Ouke, a privately held veterinary formulation and premix manufacturer founded in 1966, lists enramycin among its export products, serving Africa, Southeast Asia and South America. Its revenue is not publicly disclosed.
Threat of New Entrants: Low
Fermentation-based production requires proprietary high-yield strains, process know-how and significant capital investment.
Product registration with veterinary and feed authorities in each country is time-consuming and costly.
Established suppliers benefit from long-standing relationships with integrators and feed mills.
Bargaining Power of Suppliers: Medium
Fermentation inputs such as starch, glucose and soybean meal are commodities available from many suppliers.
Active ingredient production is concentrated among a limited number of Chinese manufacturers, giving them influence over premix formulators and brand owners.
Energy and environmental compliance costs in China can be passed through to buyers.
Bargaining Power of Buyers: High
Large integrators and feed mills purchase in volume and negotiate prices across multiple suppliers.
Generic premixes from several manufacturers give buyers choice and weaken price premiums.
Buyers can switch to alternative antibacterials or non-antibiotic products for necrotic enteritis control.
Threat of Substitutes: High
Other Gram-positive antibacterials, including avilamycin and bacitracin, address the same indication.
Probiotics, organic acids, phytogenics, enzymes and vaccines are increasingly used in antibiotic-free programmes.
Improved management, biosecurity and coccidiosis control reduce reliance on in-feed antibacterials.
Intensity of Competitive Rivalry: High
Numerous Chinese manufacturers and generic premix suppliers compete primarily on price.
The originator brand competes against generics on quality and documented efficacy.
Shrinking growth-promotion uses intensify competition for the remaining prevention and treatment demand.
Threat of New Entrants: Low; Strain and fermentation know-how, capital intensity and registration barriers.
Bargaining Power of Suppliers: Medium; Commodity inputs, but concentrated active-ingredient manufacturing.
Bargaining Power of Buyers: High; Large integrators, multiple generic sources and alternative products.
Threat of Substitutes: High; Other antibacterials and a growing range of non-antibiotic alternatives.
Intensity of Competitive Rivalry: High; Price competition among generic suppliers and against the originator brand.
Market estimates by geography (2032)
InsightAsia Pacific leads with $93.13M by 2032, while Middle East & Africa is projected to grow fastest at a 6.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $19.23M | $23.32M | $27.96M | 3.8% | 17% |
| Europe | $4.45M | $5.28M | $6.74M | 4.2% | 4% |
| Asia Pacific | $56.65M | $72.61M | $93.13M | 5.1% | 55% |
| Latin America | $17.16M | $22.69M | $29.64M | 5.6% | 18% |
| Middle East & Africa | $5.89M | $8.09M | $10.95M | 6.4% | 6% |
| Total | $103.38M | $131.98M | $168.42M | 5.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$168.42M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Poultry | $103.07M | 5.3% | 61% |
| Swine | $47.83M | 4.2% | 28% |
| Others | $17.52M | 5.6% | 10% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Enramycin Market covering market dynamics, competitive landscape, and strategic outlook.
The Enramycin Market market is projected to reach $168.42M by 2032, growing at 5.0% CAGR. The Poultry segment holds the largest share.
The global enramycin market, valued at USD 119.71 Million in 2025, is shaped by the balance between expanding livestock production, particularly of broilers, and the tightening global framework on antimicrobial use in food animals. This chapter assesses the macro and micro factors that influence demand, followed by the principal drivers, restraints, opportunities, trends and challenges.
Market Growth Factor Analysis
The table below assesses five macro-level and five micro-level factors affecting the enramycin market. Each factor is classified by impact type as promoting, inhibiting or steady, and assigned an impact score out of 10 for three forecast periods. The scores are analyst assessments based on secondary research and industry discussions, where a higher score indicates a stronger influence on the market.
Expanding Global Poultry Meat Production
Poultry is the largest and fastest-growing source of meat worldwide, and it is the core application for enramycin. The OECD-FAO Agricultural Outlook 2026–2035 projects global meat consumption to reach about 412 million tonnes by 2035, with poultry accounting for the largest increase of any meat, an expansion of around 29 million tonnes or 20%. The USDA Foreign Agricultural Service forecast global chicken meat production of 110.7 million tonnes in 2026, around 3% above the previous year, with Brazil alone producing 15.8 million tonnes and exporting about 5.2 million tonnes. Growth is concentrated in Asia, Latin America and the Middle East, where poultry is the most affordable animal protein and where commercial broiler operations are expanding rapidly. In China, poultry meat output rose 6.7% in 2025 to 28.37 million tonnes according to the National Bureau of Statistics. Each additional broiler flock raised on commercial compound feed expands the base of birds exposed to necrotic enteritis risk and therefore the potential demand for in-feed Clostridium control. Because enramycin is used at low inclusion rates and is generally dosed through premixes in starter and grower diets, its demand tracks closely with broiler placements and feed tonnage in these regions.
Economic Burden of Necrotic Enteritis
Necrotic enteritis, caused by toxin-producing strains of Clostridium perfringens, is one of the most costly enteric diseases in broiler production. Industry estimates have put its global cost at close to USD 6 billion a year, through mortality, reduced weight gain, poorer feed conversion and condemnations of carcasses affected by subclinical disease. The disease is closely linked to coccidiosis, high dietary levels of non-starch polysaccharides and animal protein, and stressors common in intensive production. Enramycin is active against Gram-positive bacteria including Clostridium perfringens, and products such as MSD Animal Health's Enradin are registered specifically for necrotic enteritis control, for example in Mexico and Indonesia. Reports from the United States, where around 60% of broiler production had moved to "No Antibiotics Ever" programmes by 2019, of renewed necrotic enteritis pressure in such flocks have reinforced awareness among producers of the cost of the disease. For integrators in markets where enramycin remains authorised, it offers a low-inclusion, locally acting tool for protecting flock performance, which sustains demand even as growth-promotion uses are curtailed.
Animal-Only Use and Favourable Safety Profile
Enramycin is not used in human medicine and is very poorly absorbed from the gastrointestinal tract, so it acts locally in the gut with minimal tissue residues. Product labels in Mexico specify a zero-day withdrawal period for Enradin F-80. In Japan, the Food Safety Commission concluded in October 2014 that the risk from resistant bacteria selected by the use of enramycin in feed was negligible, noting the absence of reported cross-resistance with structurally related agents, and enramycin remains on Japan's list of designated feed additives. These characteristics distinguish enramycin from antibiotic classes that are important in human therapy and that have been the primary target of growth-promoter bans, such as colistin, tylosin and the tetracyclines. As regulators restrict medically important antimicrobials, enramycin's profile allows it to remain available in several markets, as illustrated by Brazil, where bacitracin and virginiamycin were prohibited as growth promoters in April 2026 while enramycin was not included in the prohibition. This regulatory resilience supports continued demand, particularly in export-oriented poultry industries that must balance performance with residue compliance.
Consolidation and Integration of Livestock and Feed Production
Poultry and pig production in Asia, Latin America and the Middle East is consolidating into large vertically integrated companies that operate their own feed mills, hatcheries and processing plants. Integrated producers formulate feed centrally and incorporate additives through standardised premixes, which favours products such as enramycin premixes that can be dosed accurately at low inclusion rates. China recorded total meat output above 100 million tonnes for the first time in 2025, with a year-end hog inventory of 429.67 million head, and production is increasingly concentrated in large-scale farms. Similar consolidation is visible in Brazil, India, Southeast Asia and Saudi Arabia, where national food-security programmes encourage large poultry projects. Integrated producers also employ professional nutritionists and veterinarians who design gut-health programmes combining anticoccidials, antibacterials and alternatives, providing a structured channel through which enramycin is specified, procured and used.
Poultry Expansion in Emerging Markets
The fastest growth in poultry production is occurring in India, Southeast Asia, the Middle East and Africa, regions where regulatory frameworks still allow enramycin use in prevention and treatment and where necrotic enteritis control remains a priority. India is the fastest-growing country market in this study at a CAGR of 7.38%, and the Middle East & Africa is the fastest-growing region at 6.23%. Suppliers that establish registrations, distribution and technical support in these markets can capture a disproportionate share of incremental demand.
Repositioning Toward Veterinary-Supervised Necrotic Enteritis Control
As growth-promotion uses are restricted, enramycin can be positioned for prevention and treatment of necrotic enteritis under veterinary supervision, as in its registrations in Mexico and Indonesia. Its lack of use in human medicine, low absorption and short or zero withdrawal periods support this positioning, and the removal of competing growth promoters, as in Brazil in 2026, can create room for products that remain authorised.
Quality Differentiation and Integrated Gut-Health Programmes
Variability in the potency of generic products creates an opportunity for suppliers that can demonstrate consistent quality through GMP certification, potency testing and documented field performance. Suppliers can also combine enramycin with anticoccidials and non-antibiotic additives in integrated gut-health programmes for integrators, adding technical service value and reducing price-only competition.
Bans and Restrictions on Antibiotic Growth Promoters
The most significant restraint on the market is the progressive prohibition of antibiotics used for growth promotion. The European Union removed all antibiotic growth promoters from its feed additive register from 1 January 2006 under Regulation (EC) No 1831/2003, and Regulation (EU) 2019/6 prohibits the use of antimicrobials to promote growth or increase yield. China withdrew growth-promoting drug feed additives from 2020 under Ministry of Agriculture and Rural Affairs Announcement No. 194, removing growth-promotion claims from products with dual uses. South Korea banned antibiotics in feed in 2011, Thailand prohibited antimicrobial growth promoters, Indonesia banned antibiotics as feed additives from 2018, Vietnam phased out preventive antibiotic use in feed by the end of 2025, and Argentina banned antimicrobials for growth promotion in 2024. These measures reduce the addressable market for enramycin in its growth-promotion role and restrict it to veterinary-supervised uses in a growing number of countries.
Competition from Alternatives and Other Antibacterials
Enramycin competes with a broad range of products for the control of Clostridium perfringens and the maintenance of gut health. Other Gram-positive antibacterials, such as avilamycin and bacitracin, are approved in markets where enramycin is not, and avilamycin is the approved in-feed product for necrotic enteritis prevention in the United States. Non-antibiotic alternatives, including probiotics, prebiotics, organic acids, essential oils and phytogenics, enzymes, and functional lipids, are being adopted widely by producers pursuing antibiotic-free programmes. Generic enramycin products also exert downward pressure on prices, with the originator brand owner reporting that some generic products tested below their labelled potency, which can undermine user confidence in the molecule.
Consumer and Retailer Preference for Antibiotic-Free Meat
Retailers and food-service companies in North America, Europe and increasingly in urban Asia and Latin America have adopted sourcing policies that limit or exclude antibiotic use in meat supply chains. "No Antibiotics Ever" and "raised without antibiotics" claims have reduced the share of production in which in-feed antibacterials can be used, limiting enramycin's opportunity in premium and export-oriented supply chains.
Challenge: Product Quality and Generic Competition
Enramycin is produced by fermentation, and potency depends on strain quality, fermentation control and downstream processing. The expansion of generic premix supply, much of it from China, has increased price competition and introduced quality variability, which challenges both premium brand owners and users seeking reliable efficacy.
Challenge: Regulatory Uncertainty
The regulatory status of enramycin differs widely by country and continues to change. Suppliers must maintain registrations, residue data and labelling across many jurisdictions, and face the risk that further restrictions on in-feed antibacterials could reduce demand at short notice.
Trend: Global Commitment to Reduce Antimicrobial Use in Agri-Food Systems
In September 2024, the United Nations General Assembly adopted a Political Declaration on Antimicrobial Resistance in which countries committed to meaningfully reduce the quantity of antimicrobials used globally in agri-food systems by 2030. The World Organisation for Animal Health's ninth annual report on antimicrobial agents intended for use in animals, published in 2025, reported a 5% fall in global animal antimicrobial use between 2020 and 2022, while noting that 22% of reporting countries still used antimicrobials for growth promotion. National action plans, including China's 2021–2025 plan to reduce veterinary antimicrobial use, India's second National Action Plan on AMR launched in November 2025, and Brazil's PAN-BR AGRO, are translating these commitments into domestic measures.
Trend: Trade-Linked Antimicrobial Requirements
Importing markets are extending their antimicrobial rules to suppliers. Under Article 118 of Regulation (EU) 2019/6 and Delegated Regulation (EU) 2023/905, animals and products of animal origin exported to the European Union must, from 3 September 2026, come from animals not treated with antimicrobials for growth promotion. Meat-exporting countries are responding by tightening domestic rules, as Argentina did in 2024 and Brazil did in 2026, which shifts enramycin use in export supply chains toward documented therapeutic and preventive applications.
The enramycin value chain extends from fermentation inputs through active-ingredient manufacture and premix formulation to distribution and use on farms. Value is concentrated at the fermentation and formulation stages, where strain quality, yield and potency control determine cost and product performance.
Raw materials and inputs: Fermentation media are based on carbohydrate and nitrogen sources such as starch, glucose and soybean meal, together with mineral salts and process chemicals. Production depends on high-yielding Streptomyces fungicidicus strains. Premix production requires carriers such as corn cob meal or maize meal and packaging materials.
Manufacturing: Enramycin is produced by submerged fermentation, followed by extraction, purification and drying to obtain the active ingredient. The active ingredient is then standardised and blended onto a carrier to produce premixes, most commonly at 4%, 8% or 10% concentration. Manufacturing is concentrated in China, where large fermentation-based producers supply both their own brands and multinational brand owners under contract.
Distribution and channels: Products reach the market through animal-health companies with their own brands, regional distributors and importers, and direct sales from manufacturers to large feed mills and integrators. Registration holders in each country handle regulatory approval and technical marketing.
End users: Enramycin is incorporated into compound feed by commercial feed mills and the in-house feed mills of integrated poultry and swine producers, and used under the guidance of nutritionists and veterinarians on broiler, layer-pullet, pig and other livestock farms.
North America: In the United States, medicated feeds are governed by 21 CFR Part 558, which lists the new animal drugs approved for use in animal feeds, and the U.S. Food and Drug Administration's Guidance for Industry #213 ended growth-promotion use of medically important antimicrobials and placed their in-feed use under the Veterinary Feed Directive from January 2017. In Canada, medicating ingredients for feeds are set out in the Canadian Food Inspection Agency's Compendium of Medicating Ingredient Brochures, and prescription feeds may only use drugs approved by Health Canada. In Mexico, enramycin products such as Enradin F-80 are registered for the treatment of necrotic enteritis in broilers and pullets.
Europe: Regulation (EC) No 1831/2003 removed antibiotics other than coccidiostats and histomonostats from use as feed additives from 1 January 2006. Regulation (EU) 2019/6 on veterinary medicinal products prohibits the use of antimicrobials to promote growth or increase yield, restricts prophylaxis to exceptional cases, and, through Article 118 and Delegated Regulation (EU) 2023/905, applies the growth-promotion ban to imports from third countries from 3 September 2026. In Great Britain, the Veterinary Medicines (Amendment etc.) Regulations 2024 prohibit the use of antibiotics to promote growth or increase yield.
Asia Pacific: China's Ministry of Agriculture and Rural Affairs Announcement No. 194 of 2019 withdrew growth-promoting drug feed additives other than traditional Chinese medicines from 2020, with growth-promotion claims deleted from products that also carry prevention or treatment uses, and Announcement No. 246 cancelled the related growth-promotion product standards. In Japan, enramycin is a designated feed additive under the Act on Safety Assurance and Quality Improvement of Feed, listed by the Food and Agricultural Materials Inspection Center among additives promoting the effective use of nutrients in feed, and has been assessed by the Food Safety Commission of Japan. In India, colistin was banned for food-producing animals in 2019 and antibiotics are prescription (Schedule H) drugs. Indonesia prohibits antibiotics as feed additives under Minister of Agriculture Regulation No. 14 of 2017, Vietnam has phased out preventive use of antibiotics in feed under Decree 13/2020, and the Philippines' Bureau of Animal Industry registers enramycin 4% feed premixes.
Latin America: Brazil's Ministry of Agriculture and Livestock regulates feed additives and has prohibited specific antimicrobials as growth promoters, including tylosin, lincomycin and tiamulin under Normative Instruction No. 1 of 2020, and avoparcin, bacitracin and virginiamycin under SDA/MAPA Ordinance No. 1,617 of April 2026; enramycin is not among the prohibited substances. In Argentina, SENASA Resolution 445/2024 banned veterinary products containing antimicrobials for growth promotion or feed efficiency.
Middle East & Africa: Veterinary products, including medicated premixes, are registered by national authorities such as the Saudi Food and Drug Authority, and in South Africa feed additives and stock remedies are regulated under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
International: The World Organisation for Animal Health lists enramycin within the cyclic polypeptide class in its List of Antimicrobial Agents of Veterinary Importance, for use in poultry and swine, and the World Health Organization includes enramycin within the cyclic polypeptides class in its 2024 List of Medically Important Antimicrobials, although it is not used in human medicine.
Jul 2024: MSD Animal Health; Acquisition; Completed the acquisition of Elanco's aqua business, including the Clynav and Imvixa products, broadening its animal-health portfolio.
Oct 2025: Square Pharmaceuticals; Expansion; Board approved a BDT 650 crore balancing, modernisation, rehabilitation and expansion investment to increase manufacturing capacity.
Dec 2025: MSD Animal Health; Product Approval; Received U.S. FDA conditional approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm in cattle.
Mar 2026: China Animal Husbandry Industry Co. / Hebei Shengxue Dacheng; Acquisition; Announced the acquisition of 51% of Hebei Shengxue Dacheng Pharmaceutical and 72.7272% of Inner Mongolia Shengxue Dacheng Pharmaceutical for a total of RMB 727 million.
Jun 2026: MSD Animal Health; Acquisition; Signed a definitive agreement to acquire TARGAN, a developer of poultry hatchery technologies including chick sexing and ocular vaccine spray devices.
Aug 2026: Apeloa Pharmaceutical; Partnership; Signed a five-year strategic CDMO framework agreement with EliteX (Beijing).
Aug 2026: China Animal Husbandry Industry Co. / Hebei Shengxue Dacheng; Acquisition; Completed the public tender and obtained approval from the State Administration for Market Regulation for the Shengxue Dacheng acquisitions.
Aug 2026: Zhejiang Dayang Biotech Group; Expansion; Reported its 800 tonnes-per-year amprolium relocation and expansion project at 70% completion, with RMB 173.5 million invested.
Aug 2026: Apeloa Pharmaceutical; Business Restructuring; Restructured its active pharmaceutical ingredient segment toward specialty active ingredients, with overseas revenue at 49.5% of the total in the first half of 2026.
Political Factors
Government commitments under the 2024 UN Political Declaration on AMR drive national action plans that restrict antimicrobial use in livestock.
National food-security policies in China, India, Saudi Arabia and other countries support expansion of domestic poultry and pig production.
Economic Factors
Feed grain prices and livestock margins affect producers' willingness to spend on feed additives.
Low-cost fermentation capacity in China keeps active-ingredient and premix prices competitive and expands access in price-sensitive markets.
Currency fluctuations influence the cost of imported premixes in emerging markets.
Social Factors
Rising incomes and urbanisation increase consumption of poultry meat, the most affordable animal protein.
Consumer and retailer preference for antibiotic-free meat limits use in premium supply chains.
Technological Factors
Strain improvement and fermentation process optimisation raise yields and reduce production costs.
Improved diagnostics and gut-health monitoring support targeted rather than routine use.
Development of alternatives such as probiotics, phytogenics and vaccines creates substitutes.
Environmental Factors
Fermentation-based manufacturing generates wastewater and residual biomass subject to tightening environmental controls in China.
Antimicrobial residues and resistance in the environment are under growing scrutiny from regulators.
Legal Factors
Bans on antibiotic growth promoters in the EU, China, South Korea, Thailand, Indonesia, Vietnam and Argentina restrict permitted uses.
Product registration, maximum residue limits and withdrawal periods govern market access in each country.
Import requirements such as Article 118 of Regulation (EU) 2019/6 extend antimicrobial rules to exporting countries.
Profiles of 34 companies operating in the Enramycin Market market, including revenue, employee count, and market positioning where available.
Showing 34 of 34 companies
3 interactive charts drawn from the Enramycin Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Enramycin Market By Physical Form
Global Enramycin Market By Livestock
Global Enramycin Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
